An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer

Hoffmann-La Roche217 enrolled

Overview

This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.

Study Type

OBSERVATIONAL

Enrollment

217

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/=18 years of age * Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage III/IV) * Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start Exclusion Criteria: * Not agreeing to be followed-up (for a maximum of 24 months)

Locations (92)

Outcomes

Primary Outcomes

Progression-free survival

Time frame: 24 months

Secondary Outcomes

Best treatment response

Time frame: 24 months

Overall survival

Time frame: 24 months

Safety (incidence of adverse events)

Time frame: 24 months

Type of treatment response

Time frame: 24 months

Treatment compliance of patient

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Abbeville, France

Unnamed facility

Agen, France

Unnamed facility

Aix-en-Provence, France

Unnamed facility

Aix-en-Provence, France

Unnamed facility

Ajaccio, France

Unnamed facility

Amiens, France

Unnamed facility

Angers, France

Unnamed facility

Annecy, France

Unnamed facility

Aubagne, France

Unnamed facility

Auxerre, France

...and 82 more locations